New Seeking Alpha piece highlights how shoddy some of the thinking is surrounding this stock...the author says with a market cap of 500 million, the company is trading at 1 times peak sales for current potential indications. The market cap figure is incorrect, and to boot, almost every single analyst has peak sales just for lung cancer indication at 1b USD. If breast cancer indication has a peak sales figure of at least 1b (which it should as it is a bigger market), then that is another 1b+ USD. So even at one times peak sales, the market cap would be 2.5b for these two indications. But the usual multiple is not 1 times peak sales, but multiple times peak sales...Where on earth they get these jokers is beyond me.